RAPT Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on Nasdaq in the United States. Headquartered in South San Francisco, California, the company was incorporated in March 2015 under the name FLX Bio, Inc. and adopted the RAPT Therapeutics name in May 2019. It is best described as a clinical-stage immunology company focused on discovering, developing, and commercializing therapies for patients with inflammatory and immunologic diseases that still have significant unmet medical need. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai)) RAPT’s business model is centered on internal drug discovery and clinical development rather than on an established commercial franchise. The company has historically advanced a pipeline that included oncology and immunology assets, such as tivumecirnon (RPT475) and zelnecirnon (RPT193), but its current strategic emphasis is clearly on immunology, especially allergy-related indications. Its lead focus has shifted to RPT904, a long-acting anti-IgE antibody designed for food allergy and other IgE-mediated diseases, including chronic spontaneous urticaria. This makes the company a focused, science-driven development-stage player in a highly competitive specialty biotech segment. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai)) From a competitive standpoint, RAPT is not a large diversified pharma company; instead, it competes as a niche clinical-stage innovator. Its potential differentiation lies in immunology expertise, selective mechanisms, and the possibility of delivering more targeted treatments in underserved allergic and inflammatory conditions. That said, the company’s prospects remain heavily dependent on clinical readouts, regulatory progress, and access to capital, which is typical for a pre-revenue or early-revenue biotech company. In other words, the investment case is driven more by pipeline execution than by current commercial scale. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai)) Geographically, RAPT’s footprint is concentrated in the United States, with its principal executive offices and main operational base in South San Francisco, California, a major biotech hub. The company has also disclosed an Australian subsidiary, but its core development activities remain U.S.-centered. As a Nasdaq-listed issuer, the stock is generally sensitive to clinical updates, FDA milestones, financing events, and insider transaction disclosures, which are especially relevant in the context of SEC Form 4 monitoring. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm?utm_source=openai)) Recent milestones are notable. RAPT reported full-year 2024 results in March 2025 and said its 2025 priorities would center on advancing RPT904. In December 2024, the company raised capital through a private placement, improving its financial flexibility for ongoing development work. Most importantly, in September 2025, RAPT announced FDA clearance to proceed with a Phase 2b trial of RPT904 in food allergy, a meaningful clinical step that supports the company’s current strategic pivot toward IgE-mediated diseases. ([investors.rapt.com](https://investors.rapt.com/node/10341/pdf?utm_source=openai))